

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

NCT07348965

Status	RECRUITING
Phase	Not Applicable
Sponsor	Guangzhou University of Traditional Chinese Medicine
Enrollment	42 participants

Key Eligibility Criteria

Inclusion (8)

- Patients with non-small cell lung cancer (NSCLC) confirmed by histopathological or cytopathological examination
- Patients with EGFR exon 19 deletion or exon 21 L858R mutation
- Patients with leptomeningeal metastasis (LMD) confirmed by positive cerebrospinal fluid (CSF) cytology (within 28 days prior to the first dose administration) and with at least 1 LMD lesion that can be repeatedly evaluated by magnetic resonance imaging (MRI)
- Patients with disease progression after first-line tyrosine kinase inhibitor (TKI) treatment
- Aged ≥18 years and ≤85 years, with no gender restrictions.

... and 3 more (see full listing online)

Exclusion (9)

- Unable to complete the baseline assessment form
- Complicated with severe or uncontrolled systemic diseases, including active infection, electrolyte disturbance, bleeding tendency, etc.
- Pregnant or lactating women, or those with planned pregnancy during the study or within 6 months after the study ends
- Presence of central nervous system complications requiring emergency neurosurgical intervention
- Suffering from other malignant tumors or having a history of other malignant tumors

... and 4 more (see full listing online)

Locations (1 total)

Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China